Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Weinberger, Myron H
Constance, Christian M
Keefe, Deborah L
MetadataShow full item record
CitationCardiovasc Ther. 2010, 28(6):344-9
AbstractAliskiren is the first direct renin inhibitor approved for the treatment of hypertension. Blood pressure (BP) control in stage 2 hypertension with aliskiren monotherapy has not been reported. This was a post hoc analysis of the subgroup of patients with stage 2 systolic hypertension (baseline mean sitting systolic BP [msSBP]≥160 mmHg) who completed the 12-week monotherapy phase of a 6-month, double-blind, randomized study. A total of 175 patients were randomized to aliskiren 150 mg (n = 88) or ramipril 5 mg (n = 87) with optional up-titration to aliskiren 300 mg or ramipril 10 mg, respectively, at weeks 6 and 12. In the subgroup of patients with stage 2 systolic hypertension, aliskiren lowered msSBP and mean sitting diastolic BP (msDBP) by 22.3/12.7 mmHg from baseline to week 12; compared with a reduction of 18.1/10.2 mmHg with ramipril. The maximum BP reductions achieved with aliskiren were 60.0/34.0 mmHg (from a baseline of 172.7/107.3 mmHg). Aliskiren was noninferior (P < 0.0001) to ramipril for SBP reduction with nonsignificant superiority (P = 0.052), and superior (P = 0.043) to ramipril for DBP reduction. The proportion of patients who achieved BP control (<140/90 mmHg) after 12 weeks of monotherapy was larger with aliskiren (34/88, 38.6%) than with ramipril (22/87, 25.3%; P = 0.038). In this post hoc analysis, 12 weeks of monotherapy with aliskiren 150-300 mg provided effective mean BP reductions (22/13 mmHg) and was superior to ramipril 5-10 mg in controlling BP in patients with stage 2 systolic hypertension.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
RightsArchived with thanks to Cardiovascular therapeutics
- Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
- Authors: Uresin Y, Taylor AA, Kilo C, Tschöpe D, Santonastaso M, Ibram G, Fang H, Satlin A
- Issue date: 2007 Dec
- Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.
- Authors: Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN
- Issue date: 2010 Sep
- Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
- Authors: Andersen K, Weinberger MH, Constance CM, Ali MA, Jin J, Prescott MF, Keefe DL
- Issue date: 2009 Sep
- Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
- Authors: Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL
- Issue date: 2008 Mar
- Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
- Authors: Yarows SA, Oparil S, Patel S, Fang H, Zhang J
- Issue date: 2008 Dec